MedTrace Logo

Care-HF CArdiac Resynchronization in Heart Failure

NCT00170300 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 813

Last updated 2025-07-03

No results posted yet for this study

Summary

The CARE-HF trial evaluates the effects of Cardiac Resynchronization (CR) therapy on the mortality and morbidity of patients with heart failure due to left ventricular systolic dysfunction already receiving diuretics and optimal medical therapy.

Conditions

Interventions

DEVICE

Implantable Cardiac Resynchronisation (pacing) device

Sponsors & Collaborators

  • Medtronic

    collaborator INDUSTRY

  • Medtronic Cardiac Rhythm and Heart Failure

    lead INDUSTRY

Principal Investigators

  • John Cleland, Professor · The University of Hull; Department of Cardiology; United Kingdom

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-01-31
Completion
2005-05-31

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00170300 on ClinicalTrials.gov